Literature DB >> 28522217

Celastrol inhibits chondrosarcoma proliferation, migration and invasion through suppression CIP2A/c-MYC signaling pathway.

Jinhui Wu1, Muchen Ding1, Ningfang Mao1, Yungang Wu1, Chao Wang1, Jiabin Yuan1, Xiong Miao1, Jingfeng Li1, Zhicai Shi2.   

Abstract

Chondrosarcomas (CS) is the second most frequent tumors of cartilage origin. A small compound extracted from Thunder God Vine (Tripterygium wilfordii Hook. F.) called celastrol can directly bound CIP2A protein and effectively inhibit cell proliferation and induce apoptosis in several cancer cells. However, little knowledge is concern about the important role of CIP2A in CS patients and the therapeutic value of celastrol on CS. Our results showed that CIP2A and c-MYC were verified to be oncoproteins by detecting their mRNA and protein expression in 10 human CS tissues by qRT-PCR and Western blots. After treatment of celastrol, the proliferation, migration and invasion were significantly inhibited; whereas the apoptosis was largely induced in human CS cell lines. In addition, celastrol inhibited the expression of CIP2A, c-MYC, and suppressed apoptotic proteins BAX and caspase-8 in human CS cells, on the other hand, it induced the expression of antiapoptotic protein Bcl-2. Finally, knockdown of CIP2A also inhibited the migration and invasion and induced apoptosis of human CS cells. To sum up, we found that celastrol had effects on inhibiting proliferation, migration, invasion and inducing apoptosis through suppression CIP2A/c-MYC signaling pathway in vitro, which may provide a new therapeutic regimen for CS.
Copyright © 2017 The Authors. Production and hosting by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CIP2A; Celastrol; Chondrosarcoma; c-MYC

Mesh:

Substances:

Year:  2017        PMID: 28522217     DOI: 10.1016/j.jphs.2016.12.007

Source DB:  PubMed          Journal:  J Pharmacol Sci        ISSN: 1347-8613            Impact factor:   3.337


  8 in total

Review 1.  Targeting protein phosphatases for the treatment of inflammation-related diseases: From signaling to therapy.

Authors:  Jie Pan; Lisha Zhou; Chenyang Zhang; Qiang Xu; Yang Sun
Journal:  Signal Transduct Target Ther       Date:  2022-06-04

Review 2.  Therapeutic targeting of PP2A.

Authors:  Caitlin M O'Connor; Abbey Perl; Daniel Leonard; Jaya Sangodkar; Goutham Narla
Journal:  Int J Biochem Cell Biol       Date:  2017-10-26       Impact factor: 5.085

3.  A Tf-modified tripterine-loaded coix seed oil microemulsion enhances anti-cervical cancer treatment.

Authors:  Yunyan Chen; Ding Qu; Rongping Fu; Mengfei Guo; Yue Qin; Jian Guo; Yan Chen
Journal:  Int J Nanomedicine       Date:  2018-11-08

4.  A microfluidic chip-based co-culture of fibroblast-like synoviocytes with osteoblasts and osteoclasts to test bone erosion and drug evaluation.

Authors:  Hui-Peng Ma; Xue Deng; Deng-Yi Chen; Di Zhu; Jin-Ling Tong; Ting Zhao; Jin-Hui Ma; Yan-Qiu Liu
Journal:  R Soc Open Sci       Date:  2018-09-12       Impact factor: 2.963

Review 5.  Traditional Chinese medicine as a cancer treatment: Modern perspectives of ancient but advanced science.

Authors:  Yuening Xiang; Zimu Guo; Pengfei Zhu; Jia Chen; Yongye Huang
Journal:  Cancer Med       Date:  2019-04-03       Impact factor: 4.452

Review 6.  Mission Possible: Advances in MYC Therapeutic Targeting in Cancer.

Authors:  Brittany L Allen-Petersen; Rosalie C Sears
Journal:  BioDrugs       Date:  2019-10       Impact factor: 5.807

Review 7.  Celastrol: A Review of Useful Strategies Overcoming its Limitation in Anticancer Application.

Authors:  Jinfeng Shi; Jiaxin Li; Ziyi Xu; Liang Chen; Ruifeng Luo; Chen Zhang; Fei Gao; Jinming Zhang; Chaomei Fu
Journal:  Front Pharmacol       Date:  2020-11-18       Impact factor: 5.810

8.  Celastrol Inhibits Migration and Invasion of Triple-Negative Breast Cancer Cells by Suppressing Interleukin-6 via Downregulating Nuclear Factor-κB (NF-κB).

Authors:  Fei Yan; Zihong Wu; Zihui Li; Li Liu
Journal:  Med Sci Monit       Date:  2020-09-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.